Differentiation markers such as β-tubulin III was correlated with resistance to DNA-damaging and microtubule-interrupting chemotherapy29, 30; increased GFAP levels have been correlated with tumour volume, tumour necrosis among the GBM patients31. This evidence concerns the gene GFAP and neoplasm.